Gilead Sciences Inc. logo

Gilead Sciences Inc. (GILDCL)

Market Closed
3 Jul, 19:00
79,000. 00
CLP
0
0%
CLP
- Market Cap
17.2 P/E Ratio
3.08% Div Yield
0 Volume
6.22 Eps
79,000 CLP
Previous Close
Day Range
79,000 79,000
Year Range
72,660 110,580
Want to track GILDCL and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 31 days

Summary

GILDCL closed yesterday higher at 79,000 CLP, an increase of 0% from Wednesday's close, completing a monthly increase of 0% or 0 CLP. Over the past 12 months, GILDCL stock gained 0%.
GILDCL pays dividends to its shareholders, with the most recent payment made on Jun 27, 2025. The next estimated payment will be in In 2 months on Sep 27, 2025 for a total of 0.79 CLP.
The last earnings report, released on May 08, 2025, exceeded the consensus estimates by 0.04%. On average, the company has fell short of earnings expectations by -0.45%, based on the last three reports. The next scheduled earnings report is due on Aug 05, 2025.
Gilead Sciences Inc. has completed 5 stock splits, with the recent split occurring on Jan 28, 2013.
The company's stock is traded on 19 different exchanges and in various currencies, with the primary listing on NASDAQ (NGS) (USD).

GILDCL Chart

Chart

Empty chart
The chart has 2 Y axes displaying values, and values.
Loading, please wait...
End of interactive chart.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD

NEW YORK , July 2, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Gilead Sciences, Inc. ("Gilead" or the "Company") (NASDAQ: GILD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

Prnewswire | 2 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD

NEW YORK, June 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Gilead Sciences, Inc. (“Gilead” or the “Company”) (NASDAQ: GILD).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

Globenewswire | 6 days ago
Gilead Sciences (GILD) Beats Stock Market Upswing: What Investors Need to Know

Gilead Sciences (GILD) Beats Stock Market Upswing: What Investors Need to Know

In the latest trading session, Gilead Sciences (GILD) closed at $110.67, marking a +2.83% move from the previous day.

Zacks | 1 week ago

Gilead Sciences Inc. (GILDCL) FAQ

What is the stock price today?

The current price is 79,000.00 CLP.

On which exchange is it traded?

Gilead Sciences Inc. is listed on NASDAQ (NGS).

What is its stock symbol?

The ticker symbol is GILDCL.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 3.08%.

What is its market cap?

As of today, no market cap data is available.

What is the earnings per share?

The EPS is 1.94.

When is the next earnings date?

The next earnings report will release on Aug 05, 2025.

Has Gilead Sciences Inc. ever had a stock split?

Gilead Sciences Inc. had 5 splits and the recent split was on Jan 28, 2013.

Gilead Sciences Inc. Profile

Drug Manufacturers - General Industry
Healthcare Sector
Daniel P. O'Day CEO
XSGO Exchange
US3755581036 ISIN
US Country
17,600 Employees
14 Mar 2025 Last Dividend
28 Jan 2013 Last Split
22 Jan 1992 IPO Date

Overview

Gilead Sciences, Inc. is a frontline biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines. The company's mission revolves around addressing unmet medical needs across the United States, Europe, and other international markets. Since its inception in 1987, Gilead Sciences has been committed to pushing the boundaries of scientific research to create therapeutic solutions that can significantly improve the quality of life for patients worldwide. With its headquarters in Foster City, California, Gilead stands as a pioneer in the field, forming strategic collaboration agreements with various entities including Arcus Biosciences, Inc., Merck Sharp & Dohme Corp., and many others to bolster its research and development efforts. The company's extensive portfolio underscores its dedication to combating some of today's most challenging diseases, including HIV/AIDS, COVID-19, viral hepatitis, and certain oncological disorders.

Products and Services

  • HIV/AIDS treatment:
  • Gilead provides a robust lineup of products for HIV/AIDS management, including Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, Sunlencs, and Atripla. Each of these treatments plays a vital role in suppressing the virus, improving patient health, and reducing the risk of HIV transmission.

  • COVID-19:
  • Veklury (Remdesivir) serves as an injection for intravenous use designed to treat COVID-19. It represents one of the first antiviral treatments to receive emergency use authorization for addressing the global pandemic, demonstrating efficacy in helping hospitalized patients recover faster.

  • Viral Hepatitis:
  • Gilead offers Epclusa, Harvoni, Vemlidy, and Viread for the treatment of hepatitis B and C, contributing to the global effort to manage and potentially eliminate viral hepatitis as a major public health threat.

  • Oncology:
  • The company has made significant strides in cancer treatment with its products Yescarta, Tecartus, and Trodelvy, focusing on innovative therapies that can potentially transform the treatment landscape for patients suffering from various cancers.

  • Pulmonary Arterial Hypertension:
  • Letairis is an oral medication developed for the treatment of pulmonary arterial hypertension (PAH), aiming to improve exercise ability and delay clinical worsening in patients.

  • Severe Fungal Infections:
  • AmBisome, a liposomal formulation, is targeted at treating serious invasive fungal infections, offering a critical solution for immunocompromised patients such as those undergoing chemotherapy or with HIV/AIDS.

Across these diverse therapeutic areas, Gilead Sciences maintains a steadfast commitment to innovation, safety, and efficacy, striving to fulfill its mission of advancing healthcare and enhancing patient outcomes around the globe.

Contact Information

Address: 333 Lakeside Drive
Phone: 650 574 3000